2021 interim results - medicagroupplc.com
TRANSCRIPT
Medica RestrictedDocument classification:
medica.co.uk
2021 Interim Results
Analyst Presentation
Stuart Quin (CEO), Richard Jones (CFO) and Dr. Robert Lavis (Group Medical Director)
27 September 2021
Medica RestrictedDocument classification:medicagroupplc.com
Agenda
1. H1 2021 highlights
2. Financial review
3. Trading and market update a. UK
b. Ireland and US
4. Strategy update and FY21 outlook
5. Q&A
2
Medica RestrictedDocument classification:
HighlightsFinancial
• Strong performance across business driven by recovery and growth in out-of-hours
o UK – Elective activity largely recovered. NH remains strong with new contract wins and renewals
o US – RadMD : revenue of £1.5m in the first 3-month with strong performance since end of June
o Ireland - Revenue of £4.5m - performance in line with expectations for first full six-month period
• Strong balance sheet and cash position (Net debt: £0.04m; Cash £11.6m)
• Interim dividend declared of 1.89 pence (+4.7%)
Operational
• FutureTech programme on track. Good progress with first AI integration into clinical reporting
• MedX joint venture formed in Australia
3medicagroupplc.com
Medica RestrictedDocument classification:
Comprehensive statement of income
• Strong improvement
• LFL revenue increased
• LFL Operating Profit
5
H1 2021 H1 2021 H2 2020 H1 2020 H1’21 v H1’20
H1’21 v H2’20
H1’21 v H1’20
£’000 Underlying* LFL (UK) Underlying* Underlying* LFL (UK)
Revenue 26,436 20,415 19,833 16,981 +55.7% +33.3% +20.2%
Gross Profit 13,504 10,187 9,452 8,000 +68.8% +42.9% +27.3%
GPM 51.1% 49.9% 47.7% 47.1% +4.0% +3.4% +2.8%
Operating Profit 4,255 3,126 2,938 2,065 +106.1% +44.8% +51.4%
Operating Margin
16.1% 15.3% 14.8% 12.2% +3.9% +1.3% +3.1%
PBT 3,976 2,994 2,780 1,957 +103.2% +43.0% +53.0%
EPS (basic) 2.82 pence n/a 2.26 pence 1.21 pence +133.1% +24.8%
medicagroupplc.com
*Underlying results exclude one-off costs including costs relating to acquisitions and exceptional items
Medica RestrictedDocument classification:
Financial position
• Results in line with trading statement on
6
30 June 2021
31 Dec 2020 30 June 2020
Non-current assets 59,060 44,932 27,099
Current assets 25,478 22,267 26,174
Current liabilities (24,970) (14,123) (3,194)
Non-current liabilities (5,272) (16,623) (13,290)
Net Assets 54,296 36,453 36,789
Cash and cash equivalents
11,640 13,934 20,004
Borrowings (11,675) (17,841) (11,948)
Net Debt (35) (3,907) 8,056
• Revised balance sheet
reflects
o Acquisition of RadMD
in March 2021
o Equity fundraise in
March 2021
o Repayment of term
debt and prior RCF
and £12m of the new
RCF drawn
Medica RestrictedDocument classification:
Segmental analysis • UK o Revenues increased 20.2% YoY and 10.3% compared
to H2 2020, with continued strong NH performance and EL recovery continued throughout the period
o GM improved 2.8% YoY and 2.7% compared to H2 2020 due to cost efficiencies & improving mix
o Net margin on an improving trend as activity and revenue increased
• Irelando First full period from Ireland with a performance in line
with expectations
o Gross margin remains higher than the UK due to a different mix of activity
o Increased activity flowed through to bottom line performance with operating margin of 19%
• USo First three month period of contribution
o Gross margins higher than historic average due to better mix of full service work
7
UK Ireland US Total
H1 2021 H1 2021 H1 2021(3 months)
H1 2021
Revenue 20,415 4,529 1,492 26,436
Gross Profit
10,187 2,428 889 13,504
GPM 49.9% 53.6% 59.6% 51.1%
Operating Profit
3,126 861 268 4,255
Op Profit margin
15.3% 19.0% 18.0% 16.1%
medicagroupplc.com
Medica RestrictedDocument classification:
Cash and working capital
8
£’000 H1 2021 H1 2022 FY 2020
Cashflow from operating activities
4,571 2,874 5,683
Working capital (3,446) 2,097 2,958
Cash inflow from Op activities
1,125 4,971 8,641
Acquisition of RadMD/GDI
(11,429) - (13,813)
Capex (1,181) (1,437) (2,008)
Repayment of borrowings
(17,586) (54)
Additional borrowing 11,592 5,963
Equity Fundraise 15,607 - 1
Dividends/Interest (154) (150) (1,290)
Net change in cash (2,223) 3,428 (2,639)
• In H1 2021, as expected working capital movement reversed the positive movement in prior year (caused by debtors unwinding with the fall in revenues). Additionally:
o Irish withholding tax increased due to the cyber attack which delayed repayments leading to a WHT balance of €1.1m at the period end, this has since unwound early in H2 2021
o RadMD negative working cap in the period of $390k
o The balance of working capital movement relates to increases in debtors in the UK and Ireland as activity increased
• UK debtor days remained under 60 days
• For comparison H1 2019 working capital movement was (£3.1m)
medicagroupplc.com
Medica RestrictedDocument classification:
UK Update Core market remains strong
Richard Jones, CFO
Dr. Robert Lavis, Group Medical Director
Medica RestrictedDocument classification:
UK revenue compared to prior periods
• H1 2021 revenue increased 20.2% YoY and 10.3% vs H2 2020
• NightHawk
o Revenue grew 39% YoY
o Increased by 12% compared to H2 2020 reflecting continued strong core growth
• Elective
o Revenue reduced 8% YoY as the comparative period included a strong Q1 prior to Covid-19
o Increased 7% vs H2 2020 as the recovery in EL volumes continued through H1
10
£'000 £'000 £'000 £'000 £'000 £'000 £'000
H1 2018 H2 2018 H1 2019 H2 2019 H1 2020 H2 2020 H1 2021
NH 9,293 10,019 10,409 11,663 10,249 12,734 14,252
EL 9,299 10,358 11,569 12,901 6,732 5,783 6,163
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
UK revenue summary
Two period moving average: NH (blue), EL (pink)
Medica RestrictedDocument classification:
UK Elective activity progress FY 2021 YTD
• Elective activity has maintained positive momentum through FY 2021 to date and is now close to pre-pandemic levels (Jan-Feb 2020)
• Current growth trend expected to continue driven by
o Increasing activity from existing clients
o Demand returning from dormant clients
o New client connectionso Additional scanning
capacity (e.g. CDH locations) operational by year end
11
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
04/01/2021 04/02/2021 04/03/2021 04/04/2021 04/05/2021 04/06/2021 04/07/2021 04/08/2021 04/09/2021
Elective Units as % of Jan/Feb 20 average
Elective Units as % of budget Linear (Elective Units as % of budget)
Medica RestrictedDocument classification:
UK Teleradiology market
• Contracts secured by Framework call off, Framework mini competition, and direct OJEU Tender
• 84% of NightHawk revenue in Jun 21 from clients who have used the service for >5 years
• Increased contract renewal dialogue post COVID means 43% of NH revenue in Jun 21 from contracts/extensions signed in last 18 months (vs 36% signed in last 2 years as at Dec 20)
medicagroupplc.com
84%
5%5%
1% 3%2%
% of Jun 21 NH revenue by year service commenced
2016 (or earlier) 2017 2018 2019 2020 2021
28%
5%
14%
9%
17%
26%
% of Jun 21 NH revenue by year current contract commenced
2016 (or earlier) 2017 2018 2019 2020 2021
27%
11%
6%20%
17%
19%
% of Dec 20 NH revenue by year current contract commenced
2015 (or earlier) 2016 2017 2018 2019 2020
Excellent customer growth and retention
12
Medica RestrictedDocument classification:
UK Capacity & Quality metrics
Increase in available rostered reporting hours since December 2020
0.4%*
13
• *Focus on managing recovery in EL and maximising existing capacity in H1. After the period end, capacity has increased by >3%
• Continued fast turnaround of NightHawk studies, averaging less than 23 mins per report
• Expansion of our SameDay service, supporting enhanced hospital patient flows
• MedX JV first live reporting for UK clients
medicagroupplc.com
98% Adherence to SLA for NightHawk reporting
Medica RestrictedDocument classification:
Augmented Intelligence in the real world
Processed cases flagged as critical by qER
Faster reporting time for cases flagged as critical (= 60s)
13% 7%
14
Excellent results from first AI rollout
• 90,000+ exams processed with qER so far
• From a continuous sample of over 8000 cases processed in August:
Critical exams were reported in an average of 13 minutes 24 seconds from the receipt of the last image.
medicagroupplc.com
Medica RestrictedDocument classification:
Ireland and US update: Performance of acquisitions on track
Stuart Quin, CEO
Medica RestrictedDocument classification:
Medica Ireland update
• Strong recovery dynamics
o Overall activity was on plan, despite the ransomware attack on the Irish HSE which meant that imaging systems were unavailable for c.6 weeks meaning we were unable to report the full demand of scans
o Elective activity now ahead of pre-pandemic levels
o Growth driven by combination of demand from existing customers, plus significant number of new contract wins
o Demand for diabetic retinopathy screening and surveillance continued to grow due to our ‘Covid secure’ service
• Focus on growth
o Developing relationship with leading insurance provider
o Partnership with independent provider for reporting
o Focus on expanding hospital clients to support backlog reporting
16medicagroupplc.com
Medica RestrictedDocument classification:
US (RadMD) update
17medicagroupplc.com
• Initial delays to patient recruitment easing o RadMD acquired on 26 March. First 3 months in reporting period
has seen activity increase. Also new contract wins have converted into revenue post-period end
o Pipeline and contracted order book have both continued to grow since the period end providing good visibility and prospects for the remainder of 2021 and into 2022
• Focus on growtho New senior team in place - Chief Commercial Officer, as well as
Head of Operations, Finance Director
o Focus on new clients including medical devices and AI companies, as well as developing more strategic approach with larger existing clients
o Image acquisition and analysis system under review to improve functionality
Medica RestrictedDocument classification:
Strategy update and outlook: Delivering on strategy to meet growth targets
Stuart Quin, CEO
Medica RestrictedDocument classification:
Medica strategy
Invest in our people & systems
Telemedicine company of choice for
specialist doctors
Trusted, go-to partner
enhancing patient outcomes
Delivering profitable
growth with diversification
19
Delivering sustainable growth to enhance patient outcomes
1. Invest in our people and systems to build an
engaged and motivated team
2. Be the company of choice for specialist doctors
and clinicians wanting to expand their expertise in
telemedicine
3. Be the trusted, go-to partner for healthcare
providers with a reputation for reliability and
transparency to enhance patient outcomes
4. Deliver profitable, diversified growth
underpinned by commitment to ESG with focus
on market-leading clinical governance
medicagroupplc.co.uk
Capital Markets
Day
Medica RestrictedDocument classification:
Focus on ESG
medicagroupplc.com
• Our approach to ESG is based on the established
FTSE Russell framework for assessing ESG
performance
• ESG at Medica is governed by the board through our
dedicated subcommittee chaired by Dr. Junaid Bajwa
Capital Markets
Day
Medica RestrictedDocument classification:
Short to Medium Term Financial and Investment targets
• Group Growth Rate and Revenue Target – Growth of core UK
business at 12-14% and recently acquired US and Irish companies
by over 15% in the short to medium term with an overall target of
c.£100m revenues in 3-5 years excluding any non-organic growth
• Target Margins – Gross Margins of over 45% and underlying
operating profit margins of over 20% in the short to medium term
• Target Return on Capital Employed (ROCE) – ROCE of at least
15% within a reasonable period for such opportunities whilst looking
to maintain group ROCE above 20% overall
• Target Cash Conversion – Underlying Operating Profit to Cash
conversion of at least 80%
medicagroupplc.com 21
Capital Markets
Day
Medica RestrictedDocument classification:
Summary
➢ Strong H1 performance driven by recovery in Elective volumes and continued NH growth
➢ Positive contribution from Ireland and US to H1 results
➢ Strategy execution well underway: successful first Capital Markets Day showcased progress
➢ Opportunities to drive additional growth via selective M&A in adjacent areas of telemedicine & new geographies
➢ Outlook: ➢ Patient backlogs will continue to drive activity through
Q4 and into 2022
➢ Focus on building pipeline in imaging CRO business
medicagroupplc.com 22
Medica RestrictedDocument classification:
Future Tech Components
PACS
The Integration Layer
Orchestration
Advanced visualisation tools
AI
medicagroupplc.com
Medica RestrictedDocument classification:
Costs & Benefits
Cash payback within 5
years
Above 20% Operating Leverage
Improved Reporter
Experience & Better Clinical
Outcomes
Significant Efficiency
Gains
Significant Productivity
Gains
Costs:
Approx. £6m investment over 3 years (incl. Licences, Hardware & Staff Time)
Benefits:
medicagroupplc.com
Medica RestrictedDocument classification:
Programme Timeline
27
Q420 Q121 Q221 Q321 Q222Q122Q421 Q322 Q422
PACS1 & Integration Layer Development
AI
qER Live
PACS1 Live
PACS1 Production Ready
PACS 2aPACS
2bPACS 2c
qER Shortlisted for APMTechnology Project of the Year
Orchestration
Terarecon AV
Mirada AV
AI
Client Portal
L2P & WFM Digitise Doc Details
medicagroupplc.com